The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

The ROR inhibitors market is witnessing steady growth driven by the increasing understanding of receptor tyrosine kinase-like orphan receptor ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have been assigned a consensus recommendation of “Hold” from the seven ratings firms that are covering the company, MarketBeat ...

BioWorld - Tuesday, June 17, 2025 See today's BioWorld Home » 2seventy, TG, Springworks lead cancer index among Q1 market falls To read the full story, subscribe or sign in.

After gaining 5.78% in January, the BioWorld Cancer Index reversed course, falling 4.74% year-to-date by the end of March. The index’s movement has closely tracked broader market trends. The Nasdaq ...

2seventy bio, Inc. (Nasdaq: TSVT), today reported financial results and recent highlights for the fourth quarter and full year ended December 31, 2024. “2024 ...

Shares of 2seventy bio, Inc. (NASDAQ:TSVT – Get Free Report) have received a consensus rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat.com ...

Under the terms of the agreement, Bristol Myers Squibb will acquire 2seventy bio, with 2seventy shareholders receiving $5.00 per share in cash.

Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025.